Sigachi Industries Achieves R&D Milestone in Cystic Fibrosis APIs, Targets ₹250 Crore Revenue
Sigachi Industries has advanced a new Cystic Fibrosis (CF) API combination. The company anticipates a revenue potential of approximately ₹250 crore per annum starting from Q4 FY2026–27. This development is part of their strategy to focus on high-value specialty APIs.
The development of a new API combination in a large market like cystic fibrosis, with a projected revenue of ₹250 crore per annum, is likely to have a significant impact on the company's financial performance and market position.
The announcement details a significant R&D achievement and projects substantial future revenue, indicating positive progress and growth potential for the company.
Sigachi Industries Limited has announced a significant R&D milestone with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination, comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.
This development aligns with the company's strategy to expand its presence in complex, high-value specialty APIs, tapping into the global cystic fibrosis therapeutics market estimated to exceed USD 10 billion. Sigachi is exploring strategic collaborations for R&D and future commercial supply of these CF APIs.
Subject to successful partnerships and market progression, the company estimates a revenue potential of approximately ₹250 crore per annum, commencing from Q4 FY2026–27. Lijo Chacko, Deputy Group CEO, stated that this milestone reflects the company's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility.
The CF API combination involves advanced chemistry and specialized reactions, presenting high technological complexity and significant barriers to entry. The innovator patent protection for Vanzacaftor extends until 2039, offering sustained commercial opportunity within the cystic fibrosis therapeutic space.
What to do with a filing like this
Sigachi Industries Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sigachi Industries Limited. Read the original for the full detail.